-
Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study Lancet Oncol. (IF 41.6) Pub Date : 2025-06-03
Che L Reddy, Cecilia Sousa, Rifat AtunBackgroundHealth systems in the Commonwealth perform suboptimally in relation to cancer control. We applied a proprietary health system analysis framework to benchmark cancer control infrastructure and explore the implications for health systems to enhance the cancer response. MethodsIn this multinational, population-based observational study across all 56 Commonwealth countries, we analysed data across
-
Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope? Lancet Oncol. (IF 41.6) Pub Date : 2025-06-02
Clélia CoutzacNo Abstract
-
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study Lancet Oncol. (IF 41.6) Pub Date : 2025-06-02
Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S Denlinger, Syma Iqbal, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A Ozog, Phillip M Garfin, Geoffrey KuBackgroundZanidatamab, a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, previously demonstrated encouraging antitumour activity and a manageable safety profile in patients with treatment-refractory HER2-expressing gastro-oesophageal adenocarcinoma. Here, we evaluated the antitumour activity and safety of zanidatamab plus chemotherapy in first-line HER2-positive advanced
-
Empowering oncologists: a practical approach to overcoming barriers to clinical trial enrolment Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-06-03
Changchuan Jiang, Ryan D. Nipp, Tian Zhang -
Acquired resistance in cancer: towards targeted therapeutic strategies Nat. Rev. Cancer (IF 72.5) Pub Date : 2025-06-03
Alice Soragni, Erik S. Knudsen, Thomas N. O’Connor, Cristina E. Tognon, Jeffrey W. Tyner, Beatrice Gini, Donghwa Kim, Trever G. Bivona, Xingxing Zang, Agnieszka K. Witkiewicz, David W. Goodrich, Dadi Jiang, Seth T. Gammon, Christopher D. Willey, Paul C. Boutros, Vlad C. Sandulache, Abdullah A. Osman, Jeffrey N. Myers, Kamiya Mehla, Pankaj K. Singh, Keith S. Chan, Hongbo Gao, Himangi Marathe -
Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Jin Su Kim, Chan Hee Park, Eunyoung Kim, Hee Seung Lee, Jinyoung Lee, Jeehoon Kim, Eun Hee Kam, Sanghee Nam, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Sangwoo Kim, Galam Leem, Seungmin BangPancreatic cancer is a highly lethal malignancy with limited treatment response. Despite advancements in treatment, systemic chemotherapy remains the primary therapeutic approach for over 80% of patients, with no established biomarkers to guide drug selection. Traditional two-dimensional (2D) culture models fail to replicate the tumor microenvironment, necessitating the development of more advanced
-
Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Sramana Bhowmick, Saptak Banerjee, Viji Shridhar, Susmita MondalFerroptosis, the non-apoptotic, iron-dependent form of cell death is an unavoidable outcome and byproduct of cellular metabolism. Reactive oxygen species generation during metabolic activities transcends to Fe2+-induced lipid peroxidation, leading to ferroptosis. Cancer cells being highly metabolic are more prone to ferroptosis. However, their neoplastic nature enables them to bypass ferroptosis and
-
Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Hussein Sabit, Timothy M. Pawlik, Faisal Radwan, Mohamed Abdel-Hakeem, Shaimaa Abdel-Ghany, Al-Hassan Soliman Wadan, Mokhtar Elzawahri, Ahmed El-Hashash, Borros ArnethCancer treatment has been revolutionized by immunotherapy and nanomedicine, offering innovative strategies to overcome the tumor microenvironment (TME) complexities. However, challenges such as therapeutic resistance, off-target effects, and immune suppression necessitate advanced delivery systems and combination approaches. Recent advancements in nanoparticle-based therapies, biomimetic platforms
-
The Nature and Nurture of Carcinogenesis Cancer Discov. (IF 29.7) Pub Date : 2025-06-03
Emilia L. Lim, James DeGregoriSummary: In this issue, Li and colleagues characterize the mutational changes that accompany skin carcinogenesis in the two-stage model in mice. They demonstrate that, despite inducing thousands of mutations that can persist for almost a lifetime, mutagen-induced initiation must be followed by non-mutagenic promotion, which presumably alters tissue landscapes to mediate clonal selection for malignant
-
CAFs Defang NK Cells to Promote Breast Cancer Immunosuppression Cancer Discov. (IF 29.7) Pub Date : 2025-06-03
Mara H. ShermanSummary: Though NK cells often infiltrate the breast tumor microenvironment, they are frequently described as dysfunctional in this setting, and mechanisms limiting their antitumor cytotoxic potential are unclear. In this issue, Ben-Shmuel and colleagues show that breast cancer–associated fibroblasts interact with NK cells via established ligand–receptor pairs and in turn suppress NK-cell cytolytic
-
Before They Were Malignant Cancer Discov. (IF 29.7) Pub Date : 2025-06-03
Maria Sol Recouvreux, Sandra OrsulicSummary: A lack of understanding of how ovarian cancer originates in fallopian tube cells has hindered early detection and prevention, often resulting in diagnosis at advanced stages when treatment options are limited. In this issue of Cancer Discovery, two studies uncover critical microenvironmental changes that drive tumor initiation and progression, offering potential targets for earlier intervention
-
Co-blockade of TGFβ and PD-1 reinvigorates glioblastoma-infiltrating CD8+ T cells that characteristically upregulate TGFβR expression Clin. Cancer Res. (IF 10.0) Pub Date : 2025-06-03
A-Reum Kim, Seung Hyuck Jeon, Junsik Park, Eui-Soon Kim, Minsuk Kwon, Jihwan Yoo, Seok-Gu Kang, Su-Hyung Park, Jong Hee Chang, Eui-Cheol ShinPurpose: Clinical trials have shown limited efficacy of anti-programmed cell death protein 1 (PD-1) treatment for glioblastoma (GBM). In this study, we examined the expression of TGFbRI in GBM-infiltrating CD8+ T cells and the characteristics of TGFbRI+CD8+ T cells. We examined the ex vivo effects of co-blockade of PD-1 and TGFb on the functions of GBM-infiltrating CD8+ T cells. Experimental Design:
-
Millions could lose Medicaid coverage under US budget bill Lancet Oncol. (IF 41.6) Pub Date : 2025-06-02
Sharmila DeviNo Abstract
-
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2025-06-02
Dennis X. Beringer, Trudy Straetemans, Susana Minguet, Caterina Riillo, Lydia Lynch, Zsolt Sebestyen, Jürgen Kuball -
Current AI technologies in cancer diagnostics and treatment Mol. Cancer (IF 27.7) Pub Date : 2025-06-02
Ashutosh Tiwari, Soumya Mishra, Tsung-Rong KuoCancer continues to be a significant international health issue, which demands the invention of new methods for early detection, precise diagnoses, and personalized treatments. Artificial intelligence (AI) has rapidly become a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer care. In this review, we performed a systematic survey of the
-
Vascular Normalization Augments the Anti-tumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors Cancer Discov. (IF 29.7) Pub Date : 2025-06-02
Min Wang, Yanxing Chen, Lin Tian, Chenyi Wu, Jiaying Chen, Jiajia Hu, Runjie Huang, Yingnan Wang, Jinling Zhang, Xiao-Jie Ouyang, Liqin Wang, Ying Jin, Qi Zhao, Feng Wang, Rui-Hua XuImmunotherapy has made remarkable strides in treatment of solid tumors, but its efficacy as a single agent in cold tumor remains limited. It is urgent to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated the histone deacetylase inhibitor (HDACi), chidamide, enhanced chromatin accessibility at the promoters of effector molecules in CD8+ T cells, thereby augmenting
-
Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect Cancer Res. (IF 12.5) Pub Date : 2025-06-02
Jovanka Gencel-Augusto, Guillermina Lozanop53 is a transcription factor that functions as a tumor suppressor and the active unit of which is a tetramer. Nearly all cancers inactivate the p53 pathway, primarily through missense mutations in TP53. Most mutant p53 proteins lose their function and often exhibit increased protein stability. In addition to this loss of function, mutant p53 can drive oncogenicity through a dominant-negative effect
-
Neither small adults nor big children: Doing better for TYAs with brain tumors Clin. Cancer Res. (IF 10.0) Pub Date : 2025-06-02
Timothy A. Ritzmann, Rebecca Hodgkinson, Shaarna ShanmugavadivelA recent article presents a molecular analysis of High-Grade Gliomas in teenagers and young adults (TYAs). To maximise the benefit of this advancing knowledge we must address the basics. Here, we highlight the challenge of lengthy diagnostic intervals for TYAs, arguing that these must reduce to reap the benefits of molecular insights.
-
A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy Clin. Cancer Res. (IF 10.0) Pub Date : 2025-06-02
Debarati Bhanja, Junjia Zhu, Hannah Wilding, Jorge Benavides-Vasquez, Leonardo de Macedo Filho, Ahmad Ozair, Camille Moeckel, Aarav Badani, Jinpyo Hong, Jeffrey Sivik, Joseph J. Drabick, Colette R. Pameijer, Kim Margolin, Manmeet Ahluwalia, Alireza MansouriPurpose: Melanoma brain metastases (MBM) are common in advanced melanoma and linked to poor prognosis. Preventing MBM can improve survival and reduce morbidity. While dual-agent immunotherapy (dIT) improves survival, its role in MBM prevention is unclear. We compared MBM incidence, overall survival (OS), and brain metastasis-free survival (BMFS) between dIT and single-agent immunotherapies (sIT). Experimental
-
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Dan P. Zandberg, Jacob B. Allred, Ari J. Rosenberg, John M. Kaczmar, Paul Swiecicki, Ricklie A. Julian, Andrew S. Poklepovic, Jessica R. Bauman, Minh D. Phan, Nabil F. Saba, Edgardo Rivera, Kendrith Rowland, Diwakar Davar, Julia Cordes, Alan L. Ho, Miao Zhang, Stephanie A. Berg, Pamela N. Munster, Gary K. SchwartzJournal of Clinical Oncology, Ahead of Print.
-
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian W. Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine S. Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Marcus Lefebure, Stephanie Agresti, Jamie Hirata, Alessandra TedeschiJournal of Clinical Oncology, Ahead of Print.
-
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jeah Jung, Caroline Carlin, Roger Feldman, Ge Song, Aaron MitchellJournal of Clinical Oncology, Ahead of Print.
-
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials JAMA Oncol. (IF 22.5) Pub Date : 2025-06-01
Alexander D. Sherry, Avital M. Miller, Jnana Preeti Parlapalli, Gabrielle S. Kupferman, Esther J. Beck, Jordan McDonald, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Nina N. Sanford, Fumiko Chino, Bishal Gyawali, Christopher Booth, Pavlos Msaouel, Ethan B. LudmirImportanceAlternative end points, such as progression-free survival, are increasingly used in phase 3 randomized clinical trials (RCTs). However, alternative end points are often not valid surrogates for overall survival and quality of life (QOL) and may be less relevant to patients.ObjectiveTo determine the proportion of phase 3 RCTs with overall survival or QOL superiority.Design and SettingMeta-epidemiological
-
Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-06-01
Niki Oveisi, Eric C Sayre, Lori A Brotto, Vicki Cheng, Vienna Cheng, Sharlene Gill, Gillian E Hanley, Helen McTaggart-Cowan, Stuart Peacock, Meera Rayar, Amirrtha Srikanthan, Dani Taylor, Mikaela Barnes, Mary A De VeraBackground Colorectal cancer (CRC) affects a growing number of females. Our objective was to evaluate the impact of CRC on sexual health outcomes among females, while controlling for age. Methods We conducted a cohort study using administrative health data from the province of British Columbia (BC) including linked health visits and cancer registry from 1985–2017. The cohort included females with CRC
-
Cancer took centre stage at the World Health Assembly Lancet Oncol. (IF 41.6) Pub Date : 2025-05-30
Paul AdepojuNo Abstract
-
Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Matheus Sewastjanow-Silva, Lianchun Xiao, Ahmed Abdelhakeem, Cindy M. Pabon, Kohei Yamashita, Katsuhiro Yoshimura, Brian D. Badgwell, Naruhiko Ikoma, Larissa Meyer, Tara Sagebiel, Prajnan Das, Jenny J. Li, Jaffer A. Ajani, Mariela A. Blum-MurphyJournal of Clinical Oncology, Ahead of Print.
-
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jamie M. Jacobs, Lara Traeger, Madison Freese, Anna Barata, Richard Newcomb, Dustin Rabideau, Nora Horick, Zachariah DeFilipp, Yi-Bin Chen, Tamryn Gray, Julia Pepper, Ella Caruso, Hermioni L. Amonoo, Stephanie J. Lee, Joseph A. Greer, Jennifer S. Temel, Areej El-JawahriJournal of Clinical Oncology, Ahead of Print.
-
Cancer treatment and survivorship statistics, 2025 CA: Cancer J. Clin. (IF 503.1) Pub Date : 2025-05-30
Nikita Sandeep Wagle, Leticia Nogueira, Theresa P. Devasia, Angela B. Mariotto, K. Robin Yabroff, Farhad Islami, Ahmedin Jemal, Rick Alteri, Patricia A. Ganz, Rebecca L. SiegelThe number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer
-
Cancer treatment and survivorship statistics, 2025: An urgent call to optimize health after cancer CA: Cancer J. Clin. (IF 503.1) Pub Date : 2025-05-30
Lidia Schapira, Christine M. DuffyThe publication of the American Cancer Society’s “Cancer Treatment and Survivorship Statistics, 2025” report affirms that the number of people living in the United States with a history of cancer is rising because of advances in detection and treatment that have improved survival.1, 2 In our opinion, it also presents a new opportunity to engage all stakeholders in the discourse on cancer survivorship
-
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Jing Yang, Xiuxia Lu, Qiyan Cai, Mengmeng Liu, Tianliang Xia, Dongchun Hong, Liyuan Le, Xinke Zhang, Xing ZhangSoft tissue sarcoma (STS) is a rare, heterogeneous malignancy with limited treatment options for metastatic disease. Despite advances in immunotherapy, including PD-1 inhibitors, clinical outcomes remain suboptimal, highlighting the need for novel biomarkers and therapeutic strategies. This study investigated the role of TACC2 in STS, focusing on its impact on the immune microenvironment and immunotherapy
-
Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Xuyu Gu, Chanchan Gao, Xiangyu Su, Yaoyao Zhu, Qiyu Fang, Jia Yu, Ziming Wang, Deping Zhao, Wentian ZhangThis study aims to investigate the role of RGS2 in immune regulation in lung cancer (LC) and explore the regulatory relationship between RGS2 and BATF2 in modulating T cell exhaustion and tumor immune evasion. Single-cell transcriptome-based analysis was performed to identify CD8+ T-cell profiles and regulatory factors in six LC patients receiving neoadjuvant PD-1 blockade therapy. Mouse 3LL cells
-
Clinical approaches to overcome PARP inhibitor resistance Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Yutian Zou, Hanqi Zhang, Pangzhou Chen, Jiayi Tang, Siwei Yang, Christophe Nicot, Ziyun Guan, Xing Li, Hailin TangPARP inhibitors have profoundly changed treatment options for cancers with homologous recombination repair defects, especially those carrying BRCA1/2 mutations. However, the development of resistance to these inhibitors presents a significant clinical challenge as it limits long-term effectiveness. This review provides an overview of the current understanding of resistance mechanisms to PARP inhibitors
-
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Xiaochen Meng, Xiaoqian Li, Yi Gao, Shuyu ZhangNuclear receptors (NRs) are a superfamily of transcription factors that are involved in various pathophysiological processes. The human genome contains 48 types of nuclear receptors, including steroid hormone receptors (e.g., estrogen receptor [ER] and vitamin D receptor [VDR]), nonsteroid hormone receptors (e.g. peroxisome proliferator-activated receptor [PPAR] and retinoic acid receptor [RAR]), and
-
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Yaiza Senent, Vicente Fresquet, Victoria Jiménez, Karmele Valencia, Francisco Exposito, Patxi San Martín-Úriz, Gracián Camps, Eva Fernández-Pierola, Borja Ruiz-Fernández de Córdoba, Marisol González-Huarriz, Ibon Tamayo, Ana Remírez, Haritz Moreno, Diego Serrano, Daniel Ajona, Marta M. Alonso, Fernando Lecanda, Antonio Pineda-Lucena, Felipe Prósper, Miguel F. Sanmamed, Alfonso Calvo, Jose A. Martinez-ClimentEpigenetic modulators in combination with proapoptotic drugs have become the standard of care treatment in hematological malignancies. Conversely, these combinations have failed to demonstrate clinical efficacy in solid tumors. To address this discrepancy, we conducted a comprehensive analysis of the anti-tumor activity of epigenetic inhibitors in combination with BH3 mimetics that block anti-apoptotic
-
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Toby A. Eyre, Chan Y. Cheah, Clémentine Sarkozy, Anita Kumar, Steven Le GouillJournal of Clinical Oncology, Ahead of Print.
-
Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Giancarlo Di Giuseppe, Arif Jetha, Petros Pechlivanoglou, Jason D. PoleJournal of Clinical Oncology, Ahead of Print.
-
Results of combined therapy with pemetrexed and carboplatin in progressive ovarian cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Shakhnoza Niyozova, Sergey Kamishov, Oleg Balenkov, Odiljon Kobilov, Mirzagaleb TillyashaykhovJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page e17598-e17598, June 2025.
-
The impact of lymphocyte count dynamics on the predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitors (ICI) outcomes in patients (pts) with cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Eddy Saad, Marc Machaalani, Razane El Hajj Chehade, Wassim Daoud Khatoun, Jad El Masri, Marc Eid, Rashad Nawfal, Karl Semaan, Emre Yekeduz, Clara Steiner, Liliana Ascione, Chris Labaki, Renee Maria Saliby, Talal El Zarif, Alexander Gusev, Toni K. ChoueiriJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 2663-2663, June 2025.
-
Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jinchang Lu, Tianqi Luo, Jin WangJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 11533-11533, June 2025.
-
Assessment of smartwatch-based electrocardiogram (ECG) abnormality detection among childhood cancer survivors. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Ibrahim Karabayir, Luke Patterson, Stephanie B. Dixon, Daniel A. Mulrooney, Matthew Kalscheur, Tina Baykaner, Kirsten K. Ness, Melissa M. HudsonJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 10069-10069, June 2025.
-
A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Anna Maria Di Giacomo, Josep M. Piulats, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Karen Tonge, Lars Anders van der Veen, Michael M. F. LahnJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9613-TPS9613, June 2025.
-
Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Sherrif Ibrahim, John Strasswimmer, Nathalie Zeitouni, Suk-Young Yoo, Frank A. Seebach, Israel Lowy, Mihaela C. Cristea, Matthew G. FuryJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9612-TPS9612, June 2025.
-
A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Lucy Boyce Kennedy, Anthony P. Tufaro, Mark D. DeLacure, Anthony Visioni, Eren Berber, Daniel Raymond, Paolo Fabrizio Caimi, John C. Molina, Yee Peng Phoon, Joshua Arbesman, Jennifer S. Ko, Jan Joseph Melenhorst, Joseph J. Skitzki, Craig Steven Sauter, Brian Gastman, Thach-Giao TruongJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9611-TPS9611, June 2025.
-
A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Alexander Christopher Jonathan van Akkooi, Thomas Bennett, Sydney Ch'ng, Kerwin Frank Shannon, Michael Alexander Rtshiladze, Richard A. Scolyer, Robert V. Rawson, Monica Osorio, Rony Kapoor, Edward Hsiao, Helen Rizos, Serigne N. Lo, Alexander M. Menzies, Angela M. Hong, Georgina V. Long, Ines Esteves Domingues Pires da SilvaJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9610-TPS9610, June 2025.
-
NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Matheus Lobo, Andre Molina, Ivan Santos Filho, Manoel Coelho, Monique Celeste Tavares, Joao Paulo S. N. Lima, Rafaela Brito De Paula, Clovis Pinto, João Pedreira Duprat NetoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9609-TPS9609, June 2025.
-
Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Hong Zhu, Michael Lowe, Giorgos Constantine Karakousis, Lynn Thacher Dengel, Jay Soong-Jin Lee, Edmund Bartlett, Christina Vadala Angeles, Elizabeth Mary Gaughan, Georgia Beasley, Julia Terhune, Jie Deng, Roger Anderson, Terence Z. Wong, Kim BullockJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9608-TPS9608, June 2025.
-
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jabra Zarka, Hong Wang, Yan Zang, Amy Rose, John M. Kirkwood, Jason J. Luke, Hassane M. Zarour, Diwakar Davar, Yana G. NajjarJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9607-TPS9607, June 2025.
-
Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Hannah Kenny, Alban Linnenbach, Madalina Tuluc, Stacey Gargano, Scott W. Keith, Rita Susan Axelrod, Voichita Bar-Ad, Arielle Thal, Richard A. Goldman, David Cognetti, Adam J. Luginbuhl, Michael Topf, Michael Rabinowitz, Donald Weed, Wenyin Shi, Sara E. Lally, Carol L. Shields, Jennifer Maria Johnson, Joseph M. CurryJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9606-TPS9606, June 2025.
-
A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Gregory A. Daniels, Marjan Rajabi, Nicholas Lee, Adil Daud, Iwei YehJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9605-TPS9605, June 2025.
-
TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Stéphane Dalle, Yin Wu, Oliver Edgar Bechter, Daniel Brungs, Anna Maria Di Giacomo, Hanna Eriksson, Peter Mohr, Rossanna C. Pezo, Egle Ramelyte, Bernardo Leon Rapoport, Gareth Rivalland, Amitesh Chandra Roy, Mizuho Fukunaga-Kalabis, Geetha Krishna Kaza, Yayan Zhang, Etah Kurland, Alexander M. EggermontJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9604-TPS9604, June 2025.
-
Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Melissa Amber Burgess, Gino Kim In, Karam Khaddour, Peter M O'Neill, Sunil A. Reddy, Eric D. Whitman, James A. BiancoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9603-TPS9603, June 2025.
-
Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Reham Abdel-Wahab, Ruitao Lin, May Daher, Bin Liu, Rafet Basar, Elizabeth J. Shpall, Katy Rezvani, Adi DiabJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9602-TPS9602, June 2025.
-
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
David C. Qian, Jeffrey Switchenko, Melinda Lynne Yushak, David H. Lawson, Michael LoweJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9601-TPS9601, June 2025.
-
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Marcus O. Butler, Brendan D. Curti, Gail Iodice, Danielle M. Pastor, Joseph Elassal, Howard L. Kaufman, John M. KirkwoodJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9600-TPS9600, June 2025.
-
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Ardy Davarifar, Yana G. Najjar, Omid Hamid, Dirk Schadendorf, Michael K.K. Wong, Nikhil I. Khushalani, Paolo Antonio Ascierto, Tawnya Lynn Bowles, Mark Navarro, Giuseppe Gullo, Caroline RobertJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9599-TPS9599, June 2025.
-
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Evan Thomas Hall, George Ansstas, Shailender Bhatia, Andrew Scott Brohl, Melissa Amber Burgess, Maya Dimitrova, Ling Gao, Jeffrey Joseph Ishizuka, Evan J. Lipson, Jose Lutzky, Ann W. Silk, Jina Yun, Isaac Brownell, Judy Murray, Yvonne Marie Mowery, Ted Gooley, Steven Gore, Suzanne Louise Topalian, Paul NghiemJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9598-TPS9598, June 2025.
-
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Joseph J Sacco, Justin C. Moser, Allison Betof Warner, Ryan J. Sullivan, Diwakar Davar, Alexander Noor Shoushtari, Richard D. Carvajal, Sapna Pradyuman Patel, Anthony M. Joshua, Jessica Cecile Hassel, Mark Navarro, Rahul Marpadga, Giuseppe GulloJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9597-TPS9597, June 2025.
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号